Document:

Form of 3.125% Convertible Senior Note due 2014

 EXHIBIT 4.2 
 3.125% Convertible Senior Note due 2014 
 FACE OF NOTE 
 [UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS
AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO
CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF,
CEDE & CO., HAS AN INTEREST HEREIN.] 
 THE SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND ACCORDINGLY, THIS NOTE MAY NOT BE OFFERED OR SOLD EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, THE HOLDER AGREES (1) THAT IT WILL NOT WITHIN THE LATER OF (X) ONE YEAR AFTER THE
LAST DATE OF ORIGINAL ISSUANCE OF NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES) AND (Y) 90 DAYS AFTER IT CEASES TO BE AN AFFILIATE (WITHIN THE MEANING OF RULE 144 UNDER THE SECURITIES ACT) OF PSS WORLD
MEDICAL, INC., (THE “COMPANY”), OFFER, RESELL, PLEDGE OR OTHERWISE TRANSFER THE NOTES EVIDENCED HEREBY OR THE COMMON STOCK ISSUABLE UPON CONVERSION OF SUCH NOTES, EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF; (B) UNDER A
REGISTRATION STATEMENT THAT HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT; (C) TO A PERSON THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) THAT IS PURCHASING FOR ITS
OWN ACCOUNT OR FOR THE ACCOUNT OF ANOTHER QUALIFIED INSTITUTIONAL BUYER AND TO WHOM NOTICE IS GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, ALL IN COMPLIANCE WITH RULE 144A (IF AVAILABLE); OR (D) UNDER ANY OTHER AVAILABLE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS; AND (2) THAT IT WILL, PRIOR TO ANY TRANSFER OF THIS NOTE WITHIN THE LATER OF (X) SIX MONTHS (OR, IF THE COMPANY HAS NOT SATISFIED THE
CURRENT PUBLIC INFORMATION REQUIREMENTS OF RULE 144, ONE YEAR) AFTER THE LAST DATE OF ORIGINAL ISSUANCE OF NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES) AND (Y) 90 DAYS AFTER IT CEASES TO BE AN AFFILIATE
(WITHIN THE MEANING OF RULE 144 ADOPTED UNDER THE SECURITIES ACT) OF THE COMPANY, FURNISH TO THE TRUSTEE AND THE COMPANY SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THEY MAY REQUIRE AND MAY RELY UPON TO CONFIRM THAT SUCH TRANSFER IS
BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. IN ANY EVENT, NO AFFILIATE OF THE COMPANY MAY RESELL THIS NOTE OTHER THAN IN CONFORMITY WITH RULE 144 BEFORE ONE YEAR
AFTER THE LAST DATE OF ORIGINAL ISSUANCE OF NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES). 

 PSS WORLD MEDICAL, INC. 
 3.125% Convertible Senior Note due 2014 
  

			
	No. [            ]	 	$[            ]

 CUSIP No. 69366A AC4 
 PSS World Medical, Inc., a corporation duly organized and validly existing under the laws of the State of Florida (herein called the “Company,” which term includes any successor corporation or other entity under the
Indenture referred to on the reverse hereof), for value received hereby promises to pay to CEDE & CO., or registered assigns, the principal sum of [            ] Dollars,
$[            ] (which amount may from time to time be increased or decreased to such other principal amounts (which, taken together with the principal amounts of all other outstanding
Notes, shall not, unless permitted by the Indenture, exceed $200,000,000 in aggregate (or $230,000,000 if the Initial Purchaser exercises its option to purchase additional Notes in full as set forth in the Purchase Agreement) at any time by
adjustments made on the records of the Trustee or the Custodian of the Depositary as set forth in Schedule A hereto, in accordance with the rules and procedures of the Depositary) on August 1, 2014. 
 This Note shall bear interest at the rate of 3.125% per annum (subject to increase pursuant to Sections 5.06(d) of the Indenture) from August 4, 2008, or from
the most recent date to which interest had been paid or provided for to, but excluding, the next scheduled Interest Payment Date until August 1, 2014. Interest is payable semi-annually in arrears on each February 1 and August 1,
commencing February 1, 2009, to holders of record at the close of business on the preceding January 15 and July 15 (whether or not such day is a Business Day), respectively. Interest on this Note shall be computed on the basis of a
360-day year comprised of twelve 30-day months. 
 Payment of the principal of and premium, if any, and accrued and unpaid interest and any Extension Fee or
Additional Interest, on this Note shall be made at the office or agency of the Company maintained for that purpose in the Borough of Manhattan, The City of New York, in such lawful money of the United States of America as at the time of payment
shall be legal tender for the payment of public and private debts; provided, however, that any payment to the Depositary or its nominee shall be paid by wire transfer in immediately available funds in accordance with the wire transfer
instruction supplied by the Depositary or its nominee from time to time to the Trustee and Paying Agent (if different from Trustee). 
 Reference is made to
the further provisions of this Note set forth on the reverse hereof, including, without limitation, provisions giving the holder of this Note the right to convert this Note into cash, shares of Common Stock of the Company or a combination of cash
and shares of Common Stock, as applicable, on the terms and subject to the limitations set forth in the Indenture. Such further provisions shall for all purposes have the same effect as though fully set forth at this place. 
  

 - 2 - 

 This Note shall be deemed to be a contract made under the laws of the State of New York, and for all purposes shall be
construed in accordance with and governed by the laws of said State (without regard to the conflicts of laws provisions thereof). 
 This Note shall not be
valid or become obligatory for any purpose until the certificate of authentication hereon shall have been manually signed by the Trustee or a duly authorized authenticating agent under the Indenture. 
 [Remainder of page intentionally left blank] 
  

 - 3 - 

 IN WITNESS WHEREOF, the Company has caused this Note to be duly executed. 
  

			
	PSS WORLD MEDICAL, INC.
		
	By:	 	  

		 	Name:
		 	Title:

  

							
	 Dated:
	 		 	
	
	 TRUSTEE’S CERTIFICATE OF AUTHENTICATION
 U.S. BANK NATIONAL ASSOCIATION
 as Trustee, certifies that this is one of the Notes described
 in the within-named Indenture.

				
	 By:
	 	  
	 		 	
		 	Authorized Signatory	 		 	

  

 - 4 - 

 [FORM OF REVERSE OF NOTE] 
 PSS WORLD MEDICAL, INC. 
 3.125% Convertible Senior Note due 2014 
 This Note is one of a duly authorized issuance of Notes of the Company, designated as its 3.125% Convertible Senior Notes due 2014 (herein called the
“Notes”), limited to the aggregate principal amount of $200,000,000 (or $230,000,000 if the Initial Purchaser exercises its option to purchase additional Notes in full as set forth in the Purchase Agreement) all issued or to be
issued under and pursuant to an Indenture dated as of August 4, 2008 (herein called the “Indenture”), between the Company and U.S. Bank National Association (herein called the “Trustee”), to which Indenture and
all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties and immunities thereunder of the Trustee, the Company and the holders of the Notes. 
 In case an Event of Default, as defined in the Indenture, shall have occurred and be continuing, the principal of, premium, if any, and interest, including any Extension
Fee or Additional Interest, on all Notes may be declared, by either the Trustee or the holders of not less than 25% in aggregate principal amount of Notes then outstanding, and upon said declaration shall become, due and payable, in the manner, with
the effect and subject to the conditions and certain exceptions set forth in the Indenture. 
 Subject to the terms and conditions of the Indenture, the
Company will make all payments and deliveries in respect of the Fundamental Change Repurchase Price and the principal amount on the Maturity Date, as the case may be, to the holder who surrenders a Note to a Paying Agent to collect such payments in
respect of the Note. The Company will pay cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts. 
 The Indenture contains provisions permitting the Company and the Trustee in certain circumstances, without the consent of the holders of the Notes, and in other circumstances, with the consent of the holders of not
less than a majority in aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures modifying the terms of the Indenture and the Notes as described therein. It is also
provided in the Indenture that, subject to certain exceptions, the holders of a majority in aggregate principal amount of the Notes at the time outstanding may on behalf of the holders of all of the Notes waive any past Default or Event of Default
under the Indenture and its consequences. 
 No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the
obligation of the Company, which is absolute and unconditional, to pay the principal of, premium, if any, and accrued and unpaid interest, and any Extension Fee or Additional Interest, on this Note at the place, at the respective times, at the rate
and in the lawful money herein prescribed. 
 The Notes are issuable in registered form without coupons in denominations of $1,000 principal amount and
integral multiples thereof. At the office or agency of the Company referred to on the 

  

 - 5 - 

 
face hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be exchanged for a like aggregate principal amount of
Notes of other authorized denominations, without payment of any service charge but, if required by the Company or Trustee, with payment of a sum sufficient to cover any tax, assessments or other governmental charges that may be imposed in connection
therewith as a result of the name of the holder of the new Notes issued upon such exchange of Notes being different from the name of the holder of the old Notes surrendered for such exchange. 
 The Notes are not subject to redemption through the operation of any sinking fund or otherwise. 
 Upon the occurrence of a Fundamental Change, the holder has the right, at such holder’s option, to require the Company to repurchase for cash all of such holder’s Notes or any portion thereof (in principal
amounts of $1,000 or integral multiples thereof) on the Fundamental Change Repurchase Date at a price equal to the Fundamental Change Repurchase Price. 
 Subject to the provisions of the Indenture, the holder hereof has the right, at its option, during certain periods and upon the occurrence of certain conditions specified in the Indenture, prior to the close of business on the second
scheduled Trading Day immediately preceding the Maturity Date, to convert any Notes or portion thereof that is $1,000 or an integral multiple thereof, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as
applicable, at a Conversion Rate specified in the Indenture, as adjusted from time to time as provided in the Indenture. 
 Terms used in this Note and
defined in the Indenture are used herein as therein defined. 
  

 - 6 - 

 ABBREVIATIONS 
 The following abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full according to applicable laws or regulations: 
  

					
	TEN COM -as tenants in common	  	UNIF GIFT MIN ACT	 	
			
		  	  
	 	Custodian
		  	(Cust)	 	
			
	TEN ENT -as tenants by the entireties	  		 	
			
		  	  
	 	
		  	(Minor)	 	
			
	 JT TEN -as joint tenants with right of
 survivorship and
not as tenants in
 common
	  	 Uniform Gifts to Minors Act
  
	 	(State)

 Additional abbreviations may also be used 
 though not in the above list. 
  

 - 7 - 

 SCHEDULE A 
 PSS WORLD MEDICAL, INC. 
 3.125% Convertible Senior Notes due 2014 
 The initial principal amount of this Global Note is
$[                    ]. The following increases or decreases in this Global Note have been made: 
  

									
	 Date of
 Exchange
	  	 Amount of decrease
 in Principal Amount
 of this Global
Note
	  	 Amount of increase in
Principal Amount of
 this Global Note
	  	 Principal Amount of
 this Global Note
 following such
 decrease or increase
	  	 Signature of
 authorized signatory
 of Trustee or
 Custodian

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

	  
	  	  
	  	  
	  	  
	  	  

  

 - 8 -Form of Non-statutory Stock Option Award

 EXHIBIT 10.1 
 N O N S T A T U T O R Y S T O C K O P T I O N C E R T I F I C A T E 
 Non-transferable

 G R A N T TO 
  
  
 (“Optionee”) 

 the right to purchase from PSS World Medical, Inc. (the “Company”) 
                      shares of its Common Stock, par value $0.01, at the price of
$    .     per share (the “Option”) 
 pursuant to and subject to the
provisions of the PSS World Medical, Inc. 2006 Incentive Plan (the “Plan”) and to the terms and conditions set forth on the following page (the “Terms and Conditions”). By accepting the Option, Optionee shall be deemed to have
agreed to the terms and conditions set forth in this Award Certificate and the Plan. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. 
 Unless vesting is accelerated in accordance with the Plan, the Options shall vest (become exercisable) in accordance with the following schedule:

  

			
	 Vesting Date
  
	 	 Percent
of Option Shares Vested
  

	 	 	 

 IN WITNESS WHEREOF, PSS World Medical, Inc., acting by and through its duly
authorized officers, has caused this Award Certificate to be duly executed. 
  

							
	 PSS WORLD MEDICAL, INC.
	 	
			
	 By:                                       
                              
	 	 Grant Date:                     
	 	
		 		 		 	

 TERMS AND CONDITIONS 
 1. Vesting of Options. The Option shall vest (become exercisable) in accordance with the schedule shown on the cover page of this Award Certificate. Notwithstanding the vesting schedule, all Options shall
become fully vested and exercisable upon (i) termination of Optionee’s Continuous Status as a Participant by reason of death, Disability or Retirement, or (ii) a Change in Control. 
 2. Term of Options and Limitations on Right to Exercise. The term of the Options will be for a period of ten years, expiring at 5:00 p.m., Eastern
Time, on the tenth anniversary of the Grant Date (the “Expiration Date”). To the extent not previously exercised, the Options will lapse prior to the Expiration Date upon the earliest to occur of the following circumstances: 
 (a) Three months after the termination of Optionee’s Continuous Status as a Participant for any reason other than (i) by reason
of Optionee’s death, Disability or Retirement, or (ii) by the Company for Cause. 
 (b) Twelve months after the
termination of Optionee’s Continuous Status as a Participant by reason of Optionee’s Disability or Retirement. 
 (c) Twelve months after the Optionee’s death, if Optionee dies while employed, or during the three-month period described in subsection (a) above or during the twelve-month period described in subsection (b) above and before
the Options otherwise lapse. Upon Optionee’s death, the Options may be exercised by Optionee’s beneficiary designated pursuant to the Plan and paragraph 4 hereof. 
 (d) upon notification to Optionee that Optionee’s Continuous Status as a Participant is terminated for Cause. 
 The Committee may, prior to the lapse of the Options under the circumstances described in subsections (a), (b), (c) or (d) above, extend the time to exercise the Options as determined
by the Committee in writing. In no event may the Options be extended beyond the Expiration Date. If Optionee returns to employment with the Company during the designated post-termination exercise period, then Optionee shall be restored to the status
Optionee held prior to such termination but no vesting credit will be earned for any period Optionee was not in Continuous Status as a Participant. If Optionee or his or her beneficiary exercises an Option after termination of service, the Options
may be exercised only with respect to the Shares that were otherwise vested on or in connection with Optionee’s termination of service. 
 3. Exercise of Options. The Options shall be exercised by (a) written notice directed to the Company at the address and in the form specified by the Company from time to time and (b) payment to the Company in full for the
Shares subject to such exercise (unless the exercise is a “net” exercise or a broker-assisted cashless exercise, as described below). If the person exercising an Option is not Optionee, such person shall also deliver with the notice of
exercise appropriate proof of his or her right to exercise the Option. Payment for such Shares shall be in (a) cash, (b) Shares previously acquired by the purchaser, or (c) any combination thereof, for the number of Shares specified
in such written notice. The value of surrendered Shares for this purpose shall be the Fair Market Value as of the last trading day immediately prior to the exercise date. Alternatively, the Company may permit Optionee to exercise the Option through
a “net” exercise, whereby the Company shall retain from the Option that number of Option Shares having a Fair Market Value on the date of exercise equal to some or all of the exercise price. To the extent permitted under Regulation T of
the Federal Reserve Board, and subject to applicable securities laws and any limitations as may be applied from time to time by the Committee (which need not be uniform), the Option may be exercised through a broker in a so-called “cashless
exercise” whereby the broker sells the Option Shares on behalf of Optionee and delivers cash sales proceeds to the Company in payment of the exercise price. In such case, the date of exercise shall be deemed to be the date on which notice of
exercise is received by the Company and the exercise price shall be delivered to the Company by the settlement date. 

 4. Beneficiary Designation. Optionee may, in the manner determined by the Committee, designate a
beneficiary to exercise the rights of Optionee hereunder and to receive any distribution with respect to the Options upon Optionee’s death. A beneficiary, legal guardian, legal representative, or other person claiming any rights hereunder is
subject to all terms and conditions of this Award Certificate and the Plan, and to any additional restrictions deemed necessary or appropriate by the Committee. If no beneficiary has been designated or survives Optionee, the Options may be exercised
by the legal representative of Optionee’s estate, and payment shall be made to Optionee’s estate. Subject to the foregoing, a beneficiary designation may be changed or revoked by Optionee at any time provided the change or revocation is
filed with the Company. 
 5. Withholding. The Company or any Affiliate has the authority and the right to deduct or withhold, or
require Optionee to remit to the employer, an amount sufficient to satisfy federal, state, and local taxes (including Optionee’s FICA obligation) required by law to be withheld with respect to any taxable event arising as a result of the
exercise of the Option. The withholding requirement may be satisfied, in whole or in part, at the election of the Company, by withholding from the Option Shares having a Fair Market Value on the date of withholding equal to the minimum amount (and
not any greater amount) required to be withheld for tax purposes, all in accordance with such procedures as the Company establishes. 
 6.
Limitation of Rights. The Options do not confer to Optionee or Optionee’s beneficiary designated pursuant to the Plan and paragraph 4 hereof any rights of a stockholder of the Company unless and until Shares are in fact issued to such
person in connection with the exercise of the Options. Nothing in this Award Certificate shall interfere with or limit in any way the right of the Company or any Affiliate to terminate Optionee’s service at any time, nor confer upon Optionee
any right to continue in the service of the Company or any Affiliate. 
 7. Restrictions on Transfer and Pledge. No right or interest
of Optionee in the Options may be pledged, encumbered, or hypothecated to or in favor of any party other than the Company or an Affiliate, or shall be subject to any lien, obligation, or liability of Optionee to any other party other than the
Company or an Affiliate. The Options are not assignable or transferable by Optionee other than by will or the laws of descent and distribution, but the Committee may (but need not) permit other transfers. The Options may be exercised during the
lifetime of Optionee only by Optionee or any permitted transferee. 
 8. Restrictions on Issuance of Shares. If at any time the
Committee shall determine in its discretion, that registration, listing or qualification of the Shares covered by the Options upon any Exchange or under any foreign, federal, or local law or practice, or the consent or approval of any governmental
regulatory body, is necessary or desirable as a condition to the exercise of the Options, the Options may not be exercised in whole or in part unless and until such registration, listing, qualification, consent or approval shall have been effected
or obtained free of any conditions not acceptable to the Committee. 
 9. Plan Controls. The terms contained in the Plan are
incorporated into and made a part of this Award Certificate and this Award Certificate shall be governed by and construed in accordance with the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the
provisions of this Award Certificate, the provisions of the Plan shall be controlling and determinative. 
 10. Successors. This Award
Certificate shall be binding upon any successor of the Company, in accordance with the terms of this Award Certificate and the Plan. 
 11.
Severability. If any one or more of the provisions contained in this Award Certificate is invalid, illegal or unenforceable, the other provisions of this Award Certificate will be construed and enforced as if the invalid, illegal or
unenforceable provision had never been included. 

 12. Notice. Notices and communications under this Award Certificate must be in writing and either
personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to PSS World Medical, Inc., 4345 Southpoint Boulevard, Jacksonville, Florida 32216, Attn:
Corporate Secretary, or any other address designated by the Company in a written notice to Optionee. Notices to Optionee will be directed to the address of Optionee then currently on file with the Company, or at any other address given by Optionee
in a written notice to the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]